Market closed
Fulcrum Therapeutics/$FULC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Fulcrum Therapeutics
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Ticker
$FULC
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
45
Website
FULC Metrics
BasicAdvanced
$191M
-
-$0.16
2.03
-
Price and volume
Market cap
$191M
Beta
2.03
52-week high
$10.13
52-week low
$2.32
Average daily volume
387K
Financial strength
Current ratio
22.63
Quick ratio
22.126
Long term debt to equity
2.651
Total debt to equity
3.551
Management effectiveness
Return on assets (TTM)
-4.78%
Return on equity (TTM)
-4.07%
Valuation
Price to revenue (TTM)
2.735
Price to book
0.78
Price to tangible book (TTM)
0.78
Price to free cash flow (TTM)
-87.663
Growth
Revenue change (TTM)
2,752.05%
Earnings per share change (TTM)
-90.12%
3-year revenue growth (CAGR)
61.02%
3-year earnings per share growth (CAGR)
-59.06%
What the Analysts think about FULC
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Fulcrum Therapeutics stock.
FULC Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
FULC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
FULC News
AllArticlesVideos
Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET
GlobeNewsWire·4 days ago
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Fulcrum Therapeutics stock?
Fulcrum Therapeutics (FULC) has a market cap of $191M as of April 28, 2025.
What is the P/E ratio for Fulcrum Therapeutics stock?
The price to earnings (P/E) ratio for Fulcrum Therapeutics (FULC) stock is 0 as of April 28, 2025.
Does Fulcrum Therapeutics stock pay dividends?
No, Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders as of April 28, 2025.
When is the next Fulcrum Therapeutics dividend payment date?
Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders.
What is the beta indicator for Fulcrum Therapeutics?
Fulcrum Therapeutics (FULC) has a beta rating of 2.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.